Clinical Trials Logo

Herpes Simplex 1 clinical trials

View clinical trials related to Herpes Simplex 1.

Filter by:
  • None
  • Page 1

NCT ID: NCT06135844 Recruiting - Virus Clinical Trials

Hand Sanitizer Use for Herpes Simplex Virus-1

Start date: April 8, 2022
Phase: Early Phase 1
Study type: Interventional

The purpose of this pilot study is to determine if the use of Purell hand sanitizer alters the duration, level of pain and discomfort during treatment, and the size of the HSV-1 lesion. The duration of an HSV-1 (herpes) lesion is the primary endpoint for this study. Size, pain, and discomfort are the secondary endpoints.

NCT ID: NCT05823779 Recruiting - HIV Disease Clinical Trials

A 48 Week Observational Study of the Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects

HSVHIV
Start date: April 1, 2022
Phase:
Study type: Observational

This study is an observational, cohort, prospective study looking at the frequency of Herpes Simplex Virus (HSV) 1 and or 2 outbreaks in HIV positive patients who's HIV virus is controlled on highly active anti-retroviral therapy. We will be enrolling fifty (50) patients.

NCT ID: NCT05198570 Recruiting - Oncology Clinical Trials

Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients

Start date: September 15, 2021
Phase:
Study type: Observational

- Herpesvirus infections may be severe in immunocompromised patients, with a high risk of complications and mortality. - Recipients of hematopoietic stem cell transplant (HSCT) or patients receiving high-intensity chemotherapy for hematological malignancies are the most vulnerable individuals. - Although the worldwide prevalence of herpes simplex virus 1 (HSV-1) and varicella-zoster virus (VZV), antiviral prophylaxis in seropositive HSCT recipients has significantly reduced the rate of infection. - Acyclovir (ACV) is the first-choice drug for the prophylaxis or the therapy of that kind of infection. - Since the beginning, ACV has demonstrated to be characterized by a large interpatient variability, especially in children. - Therefore, therapeutic drug monitoring and pharmacokinetic studies may help in optimizing drug in children with malignancies.

NCT ID: NCT04710030 Active, not recruiting - Clinical trials for Mild Cognitive Impairment

Valacyclovir for Mild Cognitive Impairment

VALMCI
Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

Anti-viral treatment in Mild Cognitive Impairment (MCI) is a Phase II, placebo-controlled, 52-week trial using oral valacyclovir 4 g/day in 50 HSV seropositive, AD biomarker-positive, amnestic mild cognitive impairment (MCI) patients (eMCI and lMCI). The trial will directly address the long-standing viral etiology hypothesis of Alzheimer's disease (AD) which posits that viruses, particularly the very common herpes simplex virus-1 (HSV1) and herpes simplex virus-2 (HSV2), may be etiologic or contribute to the pathology of AD. This trial will intervene at an earlier stage (MCI). We will compare the repurposed drug valacyclovir to placebo in patients with amnestic MCI (eMCI and lMCI) in a randomized, double-blind, two-arm parallel group 52-week pilot trial. Our Phase II trial will be the first antiviral drug trial conducted in MCI.

NCT ID: NCT03282916 Active, not recruiting - Alzheimer Disease Clinical Trials

Anti-viral Therapy in Alzheimer's Disease

Start date: February 12, 2018
Phase: Phase 2
Study type: Interventional

Anti-viral therapy in Alzheimer's disease will investigate the efficacy of treating patients with mild Alzheimer's disease with the U.S.A marketed generic anti-viral drug Valtrex (valacyclovir, 500mg oral tablet). Valacyclovir, titrated to 4 grams per day, repurposed to treat Alzheimer's disease, will be compared to matching placebo in the treatment of 130 mild AD patients (65 valacyclovir, 65 placebo) who test positive for herpes simplex virus-1 (HSV1) or herpes simplex virus-2 (HSV2). The study will be a randomized, double-blind, 18-month Phase II proof of concept trial.